CASI Pharmaceuticals Inc (CASI)
3.01
-0.17
(-5.35%)
USD |
NASDAQ |
Mar 18, 16:00
3.03
+0.02
(+0.66%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 40.10M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 79.17% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 0.9552 |
Price to Book Value | 1.393 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 98.20% |
Profile
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world. |
URL | https://www.casipharmaceuticals.com |
Investor Relations URL | https://www.casipharmaceuticals.com/investor-relations/ |
HQ State/Province | Maryland |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Growth |
Next Earnings Release | Apr. 26, 2024 (est.) |
Last Earnings Release | Nov. 01, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world. |
URL | https://www.casipharmaceuticals.com |
Investor Relations URL | https://www.casipharmaceuticals.com/investor-relations/ |
HQ State/Province | Maryland |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Growth |
Next Earnings Release | Apr. 26, 2024 (est.) |
Last Earnings Release | Nov. 01, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |